Settling Yaz and Yasmin lawsuits in the Yaz and Yasmin multidistrict litigation (MDL) is a slow process, a fact recently expressed by the federal judge managing the MDL. It appears that the cause of the slow process is Bayer’s legal strategy, which U.S. District Judge David R. Herndon likened to attrition.
In a document filed in mid-February 2015, Judge Herndon described Bayer’s approach to settlement as either an effort to wear down the other parties, or an expectation that “an entire group of catastrophically injured women, for the most part, [will] simply drop their claims”.
In order to more quickly settle these Yaz and Yasmin lawsuits, of which there are 3,400 still pending, the court will request on or around July 1 that the Judicial Panel on Multidistrict Litigation (JPML) remand a group of cases to their home districts for trial.
In addition to remanding certain lawsuits, the court rescheduled the trial of a case involving the plaintiff, Pamela Schuchert, to start on June 15. According to a court document, the Schuchert trial will have a 10-day limit.
Carey Danis & Lowe represents Yaz, Yasmin, and Ocella victims. For more information about our legal services, contact our law offices by phone at 800.721.2519.References: Pharmaceutical litigation, Yaz/Yasmin